ViewReleaseInStandardHtml

ExpreS2ion will present its ExpreS2 technology platform at several key events in October and November

ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company will participate at several key events in October and November, including World Vaccine Congress, October 29-31, 2018, in Lisbon, Portugal, and Sedermeradagen, November 7, 2018, in Stockholm, Sweden. 

During these and additional scientific and business partnering meetings, ExpreS2ion will elaborate on the advantages of using the ExpreS2 platform for vaccine discovery, development and GMP production. Recent scientific publications where the platform was used include articles on malaria vaccine development and production in the esteemed Nature journals npj Vaccines (link to August 17, 2018 press release) and Nature Communications (link to October 3, 2018 press release).

These events provide excellent opportunities for us to present the ExpreS2 platform that has proven itself as a leading tool for developing difficult-to-express proteins for next generation treatments such as transmission blocking malaria vaccines. Scientific teams and biotechnology/pharmaceutical companies are welcome to book meetings with me and my fellow colleagues to discuss potential collaborations in the vaccine development and diagnostics areas,” says ExpreS2ion’s CEO Dr. Steen Klysner.

ExpreS2ion will participate in the following activities in October and November, 2018:

World Vaccine Congress, October 29-31, Lisbon, Portugal
To learn more about ExpreS2 and our proven, effective solutions for recombinant protein development and production, please visit ExpreS2ion at Booth #9 in the Exhibit Hall. More information at WVC Europe’s website.

BIO-Europe, November 5-7, Copenhagen, Denmark
To pre-arrange business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at BIO-Europe’s website.

Sedermeradagen, November 7, Stockholm, Sweden

Attend the company presentation by our CEO at this investor event by reserving a seat at Sedermeradagen’s website.

PEGS Europe (Protein & Antibody Engineering Summit), November 12-16, Lisbon, Portugal

To prearrange technical and business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at PEGS’ website.

International Conference on Vaccine R&D, November 13-15, Baltimore, MA, USA

To prearrange technical and business meetings with ExpreS2ion representatives, please contact us via email on info@expreS2ionbio.com. More information at Vaccines R&D-2018’s website.


Certified Adviser 

Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.

For further information about ExpreS2ion Biotech Holding AB, please contact:

Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
E-mail: sk@expres2ionbio.com

About ExpreS2ion

ExpreS2ion Biotechnologies ApS is the fully owned Danish subsidiary of Sweden-based ExpreS2ion Biotech Holding AB with company registration number 559033-3729. The subsidiary holds a unique proprietary platform, ExpreS2, made for fast and efficient development and robust production of complex proteins with focus on new vaccines, immune therapy and diagnostics. Since it was founded in 2010, the company has produced more than 250 proteins and 35 virus-like particles (VLPs) for and in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. Additionally, ExpreS2ion develops novel vaccines & immune therapies based on a ground-breaking VLP platform through its Danish joint venture AdaptVac ApS, founded in 2017.